Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like we're gaining some traction. Hopefully some positive news is PRed this upcoming week to give the SP an even bigger nudge. Monday should be interesting.
Same Charlie story, different news outlet:
http://www.edmontonsun.com/2016/12/02/experimental-hiv-treatment-has-suppressed-virus-says-charlie-sheen
Nice price movement today!
That's from 2015 if I remember correctly. It really puts in to context the need/market there is for HIV/AIDS. I'm really thirsting for an update here....its 30 patients.
If they heard, they have 2 or 3 days to report that information as its materially significant. The FDA added INNV to their SRO list - so we'll hear soon enough either way.
I'm glad I listened to that conference call to learn absolutely nothing new. I need to know why enrollment for combo therapy isn't full - only 30 patients!!!!
Although, I did find it interesting that Nader couldn't say anything about Big Pharma partnership because of an NDA.
Have patience. If you're not willing to hold on at these levels for another year possibly, then this stock isn't for you. I'm actually hoping we maintain these levels for another 2-3 weeks so I can increase my position.
I took part in 1 of Paulson's IPOs for CytoDyn and that is exactly what they preach there - sell your shares for a profit and hold on to 5-year warrants. I could have taken that road and sold at $1.50; however, I view CytoDyn as an investment just as you do. Additionally, the company made it easier for investors to exercise their warrants and sell them.
IMO the SP reflects what the latest offering was at ($0.75/share) and the risk that PRO-140 brings (as it still isn't approved). The science isn't going to change - monoclonal antibodies have proven to be safe (especially PRO-140) and the future of medicine.
The only thing that's bothering me is how long it is taking to fill these trials. Once we get word of combo being filled and first patient for monotherapy being injected, then we'll start to see the SP move up a little because we'll have a firm deadline for trial completion.
It's going to take patience, but I am holding long.
Huge spike in volume there. What do my technical people have to say about this stock currently?
Hold tight. No one said this is going to be a good short term stock. We have 2 upcoming catalysts that should give clarity to the timelines for potential approval. It's still disruptive to the standard of care.
Is this run over 11,000 shares being purchased by an insider? Or did it finally bounce off the floor?
Things could get interesting around here very soon:
http://www.kctv5.com/story/33387325/biomontr-labs-to-provide-testing-services-for-cytodyn-pro-140-clinical-trials
I won't be able to listen to the call until a few hours from now. Very interested to know the sentiment among the rest of the investors/board followers here.
What are you doing with $30 billion, Gilead?
http://finance.yahoo.com/video/blockbuster-biotech-deal-coming-214100141.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANmNDBwZHFsYnVvM2w2BGcDZFhWcFpEeHVjejQzWVRNd05USm1NUzFtTXpRNExUTmlPREF0WWpFellpMWhNMlEzTW1Sa01ERXpNV0k4Wm1sbGJHUStaMmxzWkE9PQRsYW5nA2VuLVVTBG9yaWdfbGFuZwNlbgRvcmlnX3JlZ2lvbgNVUwRwb3MDMgRyZWdpb24DVVMEc3ltYm9sA0dJTEQ-?.tsrc=applewf
This is not a stock you want to be out on. You never know when or what big pharma will gobble CYDY up.
They won't name Cytodn because they don't want our shares to spike:
http://www.forbes.com/sites/kenkam/2016/09/19/who-is-gilead-about-to-buy/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix#1542428d1548
It's only a matter of time though really
This has bothered me the most. I understand that the criteria were difficult initially... But how is this trial not filled given the historical results of PRO-140. There are over a million people with HIV!
Where did you see that last patient was injected?
Speaking of buyout... This is why I'll never be all-out on CytoDyn:
https://www.thestreet.com/story/13742818/2/gilead-gild-stock-down-jefferies-5-billion-debt-offering-suggests-imminent-deal.html
Just in case someone comes with an offer that can't be refused.
Surprised they did an offering for a share price of $0.75. Looks like we will slide down there after all even though 20 million issued shares is nothing compared to the potential return here.. Should be great for people to load up at least.
I heard nothing positive outside of the patients in the 2b extension still have fully suppressed viral loads. Very disappointed with these trial delays.
No good news... More trials delays and orphan drug status was withdrawn. Going to need some serious patience here.
Still waiting for approval, "remains positive" it will get approved
Still waiting for approval, "remains positive" it will get approved
I'm long and see it quite differently. CYDY is only going to trade on news from here out, specifically news of when last patient is injected so we have a firm deadline when trials will be completed. As a long, I like that there is low volume because it means people understand the value and are holding. No point in day trading this thing right now.
I noticed the shares reset on the Apple stock app for a few stocks. Never seen it happen before but the volume was 100k+ I believe before the reset.
Great news today! I wouldn't be surprised if they enroll the last patient for adjunct within a couple months.
Just speculating, but it's probably to monitor if they end up with any resistance to HAART. We already know that PRO 140 doesn't create resistance because it's a monoclonal antibody. Those would be good questions to ask IR though.
You're talking about an entirely new-ish market with using PRO 140 for treatment-naive HIV patients during the 2 weeks while they receive their genotype lab work back. I, too, am very surprised this hasn't gained more attention because you're talking about further increasing the market for PRO 140. Very excited to see when they submit their protocol for this use and what the FDAs response is.
I haven't listened to the CC yet, but the general concensus from the board sounds very positive. Still disappointing that adjunct isn't full and monotherapy hasn't started. Great, and unexpected news though that the patient requirements amount was cut in half. That will at least save time and money getting PRO 140 to market.
Sounds like Charlie is really pushing for this reality show.
Last month, he told Piers Morgan he gets “the future of HIV treatment" (a drug called Pro 140). The actor also noted last year in an open letter for the Today show that his viral load was “undetectable.”
Behind the Sheens! Charlie has 'met with producers' about a new reality show documenting his life with HIV
Last week Sheen physician Dr Robert Huizenga told Entertainment Tonight that the Hot Shots star is 'doing phenomenal' healthwise.
'He's on a new experimental medication for HIV,' he confirmed.
He is living up to his promise to use his celebrity status not only to alert the country and the world of these incredible needs for better HIV treatment — especially in the over two-thirds or three-quarters that aren't getting proper HIV medication — but he's also kind of pioneering the way with new treatments.
'I'm really proud of everything he's done and his continued commitment to HIV education,' he added.
Huizenga, an associate clinical professor of medicine at UCLA and a The Biggest Loser regular, testified at the time of Sheen's revelation that the viral load in his blood wa
Outside of GvHD trial starting, I don't see any good news coming out of this CC either. Guess we'll hear soon enough.
Based off of clinicaltrials.gov it looks like phase III monotherapy still hasn't started which is disappointing: https://clinicaltrials.gov/ct2/results?term=Pro+140&Search=Search
Can they delay posting that a trial has started?
That sheds some light on the difficulty of enrolling patients.
Still, there are ~50,000 cases of AIDS in the US every year. Granted, not everyone who gets AIDS is on medication, let alone multiple classes of the drugs and experiencing virological failure from all of them. I can see how the exclusion criteria can make it difficult to enroll patients, but the numbers seem to be there to be able to fill a 300 person trial. Maybe I overestimate the amount of people that would be eligible for their trial.
With respect to monotherapy and the last CC, Dr. Nader stated that the FDA requested that they tweak their protocol, which is an understandable delay.
With respect to the adjunct trial, they have a number of different sites across the US where they can conduct their trials, and enough people with HIV (CCR5 tropic) to fill them. The majority of HIV patients and the vast majority of newly infected have the CCR5 tropism - so it definitely makes one wonder why it's taking this long. It's been a question I've asked myself as well. I would have figured that at least adjunct would have filled up by now. Hopefully tomorrows CC brings positive news on this front.
I would love if you could provide a TA of today's chart if you get a chance. It seems there is some downward pressure on it but it is holding. That's just my opinion but you seem much more knowledgeable when it comes to reading charts.
Very good synopsis/foresight with your post. Even with approving 100M AS and assuming they are utilized - you're still looking at marginal dilution because of the multibillion market the drug is targeting. The only negatives I see with this upcoming CC is dilution (which is to be expected), and further trial delays. Possible good news could be a number of different events: start of monotherapy, final patient injected for adjunct, start of GvHD trial, initiation of trials for breast or prostate cancer, partnership, licensing deal, etc. Stay tuned!
I just find it odd that multiple insiders are selling relatively large quantities of shares on the cusp of good news that they've increased their revenue projections and had a drug approved to sell in Europe.
Haha, right? There were 2 other insiders that sold off significant amounts of shares too.
Anyone care to make sense of this:
Gilead Sciences Insider Sells 112,000 Shares
http://finance.yahoo.com/news/gilead-sciences-insider-sells-112-152955116.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZAM1cm5sN2poYm52bW84BGcDZFhWcFpEeHVjejR5TWpGbU1UTTROaTB4TVRZeExUTXpPVGd0WVRreFlTMW1aVGc1T1RReU9EVTBaakE4Wm1sbGJHUStaMmxzWkE9PQRsYW5nA2VuLVVTBG9yaWdfbGFuZwNlbgRvcmlnX3JlZ2lvbgNVUwRwb3MDMQRyZWdpb24DVVMEc3ltYm9sA0dJTEQ-?.tsrc=applewf
Maybe they're gearing up (or down) for a BO of a company?
Too bad none of these recent articles name the company and drug.
http://www.tv3.ie/xpose/article/entertainment-news/209492/Charlie-Sheen-trying-new-medication-for-HIV